Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $522.37, generating approximately $4.96 million. Her remaining stake totaled 324,443 shares, valued at roughly $169.5 million.
- United Therapeutics reported quarterly EPS of $5.82, below the $7.00 analyst consensus, while revenue of $781.5 million also missed expectations and declined 1.6% year over year.
- Analysts maintain a “Moderate Buy” consensus rating, with 11 Buy ratings and two Holds and an average price target of $648.33; institutional investors own 94.08% of the stock.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $522.37, for a total transaction of $4,962,515.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $169,479,289.91. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Price Performance
NASDAQ:UTHR opened at $525.82 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company's 50-day simple moving average is $544.65 and its 200 day simple moving average is $532.54. The firm has a market capitalization of $22.32 billion, a P/E ratio of 19.41, a PEG ratio of 1.75 and a beta of 0.58.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. During the same quarter last year, the company posted $6.63 EPS. United Therapeutics's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the company. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a report on Thursday, June 11th. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $648.33.
View Our Latest Analysis on UTHR
Institutional Trading of United Therapeutics
Several large investors have recently added to or reduced their stakes in UTHR. Avoro Capital Advisors LLC increased its position in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP raised its holdings in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC lifted its position in shares of United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock valued at $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Finally, Norges Bank bought a new position in shares of United Therapeutics in the fourth quarter worth about $293,418,000. 94.08% of the stock is currently owned by institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
